Medtronic plc (NYSE:MDT) is one of the 10 best healthcare equipment stocks to buy according to hedge funds.
On February 19, Truist analyst Richard Newitter reduced the price target on Medtronic plc (NYSE:MDT) from $107 to $103, while maintaining a Hold rating. Newitter noted that the company delivered modest organic revenue and a slight EPS beat while reaffirming its FY26 outlook. He highlighted relatively solid performance across the business with results exceeding street expectations in three of four segments. Strength in the Diabetes and Cardiovascular divisions helped offset weaker performance in Neurosciences.
On February 18, Barclays analyst Matt Miksic maintained an Overweight rating for Medtronic plc (NYSE:MDT). In the process, he also increased the stock’s price target from $116 to $118, which yields a revised upside of almost 22%.
Miksic highlighted Medtronic’s delivery of solid third-quarter earnings beat. However, the stock’s reaction was tempered following the company’s preliminary commentary outlining potential positives and challenges for fiscal 2027.
Medtronic plc (NYSE:MDT) is a healthcare technology company that sells device-based medical therapies. It covers more than 70 chronic diseases and sells therapies to healthcare networks, clinicians, physicians, and also directly to patients. The business operates in four segments: Cardiovascular, Diabetes, Medical-Surgical, and Neuroscience.
While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. This article is originally published at Insider Monkey.
